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A B S T R A C T
Background and objective: Although several studies have assessed the effect of folate supplementation on
lipid proﬁles among patients with metabolic diseases, ﬁndings are inconsistent. This review of
randomized controlled trials (RCTs) was conducted to summarize the evidence on the effects of folate
supplementation on lipid proﬁles among patients with metabolic diseases.
Methods: Randomized-controlled trials (RCTs) published in PubMed, EMBASE, Web of Science and
Cochrane Library databases up to until 20 August 2017 were searched. Two review authors independently
assessed study eligibility, extracted data, and evaluated risk of bias of included studies. Heterogeneity
was measured with a Q-test and with I2 statistics. Data were pooled by using the ﬁx or random-effect
model based on the heterogeneity test results and expressed as standardized mean difference (SMD)
with 95% conﬁdence interval (CI).
Results: A total of thirteen randomized controlled trials were included. Folate supplementation did not
affect systolic blood pressure (SMD 0.87; 95% CI, 1.83, 0.09) and diastolic blood pressure (SMD 0.59;
95% CI, 1.55, 0.37), and lipid proﬁles including triglycerides (SMD 0.10; 95% CI, 0.42, 0.63), total- (SMD
0.06; 95% CI, 0.31, 0.43), HDL- (SMD 0.04; 95% CI, 0.36, 0.44), VLDL- (SMD 0.08; 95% CI, 0.24, 0.41),
and LDL-cholesterol (SMD 0.14; 95% CI, 0.55, 0.28).
Conclusions: Folate supplementation did not affect blood pressures and lipid proﬁles among patients with
metabolic diseases. Additional prospective studies regarding the impact of folate supplementation on
blood pressures and lipid proﬁles in patients with metabolic diseases are necessary.
© 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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People with metabolic diseases, type 2 diabetes mellitus
(T2DM), cardiovascular disease (CVD) and polycystic ovary
syndrome (PCOS) frequently have a comorbid dyslipidemia that
increases risk of atherosclerosis and all-cause mortality [1–4]. In
addition, subjects with diabetes mellitus have an approximately
two-fold increased risk of CVD compared with subjects who do not
have diabetes [5]. This dyslipidemia is characterized by increased
concentrations of triglycerides and reduced concentrations of
high-density lipoprotein cholesterol (HDL-cholesterol, while total
cholesterol and low-density lipoprotein cholesterol (LDL-choles-
terol) may be either normal or elevated [5],6].
Correcting dyslipidemia decreases the risk of CVD and other
metabolic complications for both patients with diabetes and those
without. Several studies have explored the effects of improving the
lipid proﬁles by using lipid-altering agents and evaluating the
changes in incidence or risk of CVD and have included patients
with diabetes in the study population [7,8]. These clinical trial data
indicate that lowering total-, LDL-cholesterol and triglycerides as
well as elevating HDL-cholesterol may be beneﬁcial in reducing the
risk of coronary heart disease (CHD). Previous studies have showed
that low levels of folate, B12, and hyperhomocysteinemia were
prevalent in people with T2DM [9] and CHD [10]. Recently, folate
supplementation is suggested to control lipid proﬁles among
patients with metabolic diseases. In a study by Vijayakumar et al.
[11], it was observed that folate supplementation for 12 weeks
among women with T2DM reduced serum homocysteine concen-
trations, increased serum folate and vitamin B12 concentrations,
and lowered lipid proﬁles. Furthermore, a meta-analysis study
demonstrated that folate intake was effective in the primary
prevention of cerebrovascular events (CVCE) among patients with
hypertension and hyperhomocysteinemia (HT/HHcy), as well as
reducing the blood pressure and total homocysteine levels [12].
However, folate supplementation at a dosage of 5 mg/day for 4
weeks did not affect lipid proﬁles in familial hypercholesterolemia
[13]. Such controversial ﬁndings complicate approaches to
prescribe folate for these patients. Numerous RCTs have been
conducted to assess whether folate supplementation has a causal
effect on lipid proﬁles among subjects with metabolic diseases. We
aimed to systematically review the current evidence on the effect
of folate supplementation on lipid proﬁles in RCTs and to
summarize the available ﬁndings in a meta-analysis, if possible.
2. Methods
2.1. Search strategy
Relevant studies were systematically searched from online
databases PubMed, EMBASE, Web of Science and Cochrane Library
databases up to 20 August 2017. Search terms included: patients
[“diabetes” OR “type 2 diabetes mellitus (T2DM)" OR ‘type 1
diabetes mellitus (T1DM)" OR “non-alcoholic fatty liver disease
(NAFLD)" OR “acute myocardial infarction (AMI)" OR “coronaryartery disease (CAD)" OR ‘metabolic syndrome (MetS)" OR
“polycystic ovary syndrome (PCOS)"]; intervention (“folate” OR
“folic acid” AND ‘supplementation’ OR “intake’) and outcomes
[‘systolic blood pressure (SBP)" OR “diastolic blood pressure (DBP)"
OR “total-cholesterol” OR “triglycerides’ OR ‘LDL-cholesterol’ OR
“HDL-cholesterol’ OR ‘VLDL-cholesterol’]. References cited in the
selected studies were manually searched for additional relevant
articles. Our search was restricted to studies published in the
English language.
2.2. Selection criteria
The eligibility criteria were: human RCTs, patients with
metabolic diseases, and administration and/or supplementation
of folate or folic acid supplements. Studies that did not report mean
changes of lipid proﬁles, along with standard deviation (SD) for the
intervention and control groups, the abstracts of seminars without
full text, case reports, and studies that did not obtain the minimum
required score of quality assessment process were excluded.
2.3. Quality assessment
Data extraction and study quality assessment was conducted
by three independent researchers (RT, MA, ZA)), according to
Cochrane Collaboration Risk of Bias tool. The scale includes 3
domains related to quality of clinical trials: 1) random sequence
generation description (0 = no description; 1 = inadequate de-
scription; 2 = adequate description); 2) blinding process (2 = dou-
ble-blinding with adequate description; 1 = double-blinding with
inadequate description; 0 = wrong usage of double-blinding), and
3), and withdrawal of patients (1 = the number and reasons of
patients withdrawal described; 0 = otherwise). In the event of
disagreement, resolved by discussion until consensus was
reached.
2.4. Statistical methods
RevMan software (Cochrane Review Manager, version 5.2) and
STATA version 12.0 (Stata Corp., College Station, TX) were used for
data analyses. Heterogeneity was evaluated through the Cochran
(Q) and I-squared tests (I2). Given the existing heterogeneity
between studies, when I2 exceeds 50% or P < .05, the random-effect
model was used; otherwise, the ﬁxed-effect model was applied.
Inverse variance method and Cohen statistics were used for
estimation of standardized mean difference (SMD) and 95% CI for
verifying the outcomes behavior of each study group (intervention/
control). Sensitivity analyses also undertook in the trials one by
one to evaluate the reliability of the pooled mean difference. In
addition, the Cochrane Collaboration Risk of Bias tool was used to
assess the methodological quality of the RCTs. Potential publica-
tion bias was assessed through visual inspection of funnel plots
and quantitatively assessed using Egger’s tests.
Articles identified through 
electronic database search (n=322)
Articles screened by title and 
abstract (n=993)
Full text articles assessed for 
eligibility (n=96)
Studies included in this study 
(n=13)
Article excluded (n=902) due to duplicate 
articles, not randomized controlled trials, 
review and not human 
Excluded non-relevant articles (n=897)
Articles excluded (n=83):
1. Not metabolic disease (n=62) 
2. Data presentation inappropriate for meta-
analysis (n=9)
3. Irrelevant outcomes (n=12)
electronic d tabase search 
(n=1895)
Fig. 1. Literature search and review ﬂowchart for selection of studies.
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3.1. Search results
Searching in literature by using electronic databases identiﬁed
1895 articles. The details of step by step to study selection were
described in Fig. 1. Identiﬁed studies were screening by titles and
abstracts. Then, we were removed the duplicates and studies with
lower quality. Finally, 13 studies from 7 countries were included
into meta-analysis. Five studies were conducted in Iran, two were
performed in Italy, and one was conducted in each counties,
including Australia, UK, Turkey, Germany, Canada, and Taiwan.
3.2. Characteristics of included studies
Finally, 13 studies were included into meta-analysis which 10
were double-blind design, 2 were randomized placebo-controlled
trial design, and one was cross-over design. Eight of included
studies were assessed the effects of folate supplementation on
lipid proﬁles in patients with metabolic diseases without diabetes
and ﬁve of them were evaluated in diabetic patients. The number of
studies that have reported of mean difference of SBP, DBP,
triglycerides, total-, HDL-, LDL-, VLDL-cholesterol was 6, 6, 11,
10, 9, 10, 3, respectively. The dosage of folate used was 1 to 10 mg/
day among included studies. The duration of intervention was 2 to
12 weeks among included studies. Table 1 shows the character-
istics of included primary studies into meta-analysis.
3.3. The effects of folate supplementation on blood pressures
Results of the current meta-analysis showed that folate
supplementation did not affect SBP (SMD 0.87; 95% CI, 1.83,
0.09) and DBP (SMD 0.59; 95% CI, 1.55, 0.37) (Fig. 2 and Table 2).
Similarly, in subgroup analyses, the ﬁndings showed that no
signiﬁcant association between folate supplementation and blood
pressures based on type of disease, dosage of folate used, and the
duration of study (Table 3 & Fig. 2).
3.4. The effects of folate supplementation on lipid proﬁles
The current meta-analysis demonstrated that folate adminis-
tration did not inﬂuence lipid proﬁles, including triglycerides (SMDTable 1
Characteristics of participants in the randomized controlled trials of folate supplement
Authors (y) Country/
year
Number of
participants
Duration of study
(week)
Populatio
Folate/control
Gargari et al. [27] Iran/2011 24/24 8 Overweig
diabetes
Mangoni et al.
[28]
Australia/
2005
13/13 4 Patients 
Asemi et al. [24] Iran/2014 27/27 8 Women w
Talari et al. [29] Iran/2016 30/30 12 Patients 
Khiavi et al. [26] Iran/2011 34/34 8 Patients 
Kilicdag et al. [30] Turkey/
2005
14/17 12 Women w
Setola et al. [31] Italy/2004 25/25 8 Patients 
Solini et al. [32] Italy/2006 30/30 12 Overweig
Title et al. [33] Canada/
2006
19/19 2 Patients 
Doshi et al. [34] UK/2002 16/17 6 Patients 
Sheu et al. [25] Taiwan/
2005
36/38 12 Obese w
Fakhrzadeh et al.
[35]
Iran/2009 18/19 8 Patients 
Schneider et al.
[36]
Germany/
2014
28/28 8 Patients 0.10; 95% CI, 0.42, 0.63), total- (SMD 0.06; 95% CI, 0.31, 0.43),
HDL- (SMD 0.04; 95% CI, 0.36, 0.44), VLDL- (SMD 0.08; 95% CI,
0.24, 0.41), and LDL-cholesterol (SMD 0.14; 95% CI, 0.55, 0.28)
(Fig. 3 and Table 2).
Because of existence heterogeneity between included studies,
we used subgroup analysis by suspected variables, including type
of diseases, dosage of folate used, and the duration of study.
Findings showed that the reduction heterogeneity in a number of
subgroups, speciﬁcally in dosage of folate and the duration of study
on total cholesterol and triglycerides was observed (Table 3).ation.
n Dosage of folate (mg/
day)
Folate plus vitamins B6
or B12
ht and obese men with type 2 5 NO
with type 2 diabetes 5 NO
ith polycystic ovary syndrome 5 NO
with metabolic syndrome 5 NO
with type 2 diabetes 5 NO
ith polycystic ovary syndrome 2.5 NO
with metabolic syndrome 5 Yes
ht subjects 2.5 NO
with type 2 diabetes 10 NO
with coronary artery disease 5 NO
omen 5 NO
with hypertension 5 NO
with diabetic nephropathy 5 NO
Fig. 2. Meta-analysis of blood pressures standardized mean differences estimates for (A) for SBP, and (B) for DBP in folate and placebo groups (CI = 95%).
Table 2
Estimation of the standardized difference means of related indictors with CI 95% between the intervention and placebo groups.
Variable Number of study Standardized mean difference CI 95% Heterogeneity
I-squared (%) Q P-value
Systolic blood pressure Intervention group (after vs. before) 6 0.92 1.81, 0.03 90.7 53.51 <.0001
Placebo group (after vs. before) 6 0.23 0.56, 0.10 44.8 9.06 .107
Intervention group vs. placebo group 6 0.87 1.83, 0.09 92.0 62.81 <.0001
Diastolic blood pressure Intervention group (after vs. before) 6 0.84 1.39, 0.29 77.2 21.91 .001
Placebo group (after vs. before) 6 0.22 0.66, 0.22 67.6 15.44 .009
Intervention group vs. placebo group 6 0.59 1.55, 0.37 92.3 64.75 <.0001
Triglycerides Intervention group (after vs. before) 11 0.42 0.97, 0.12 89.1 91.47 <.0001
Placebo group (after vs. before) 11 0.33 0.82, 0.16 87.1 77.27 <.000
Intervention group vs. placebo group 11 0.10 0.42, 0.63 88.0 83.29 <.0001
Total cholesterol Intervention group (after vs. before) 10 0.45 0.99, 0.09 87.7 72.99 <.001
Placebo group (after vs. before) 10 0.35 0.68, 0.02 69.7 29.7 <.001
Intervention group vs. placebo group 10 0.06 0.31, 0.43 74.9 35.93 <.001
LDL-cholesterol Intervention group (after vs. before) 9 0.43 0.80, 0.13 81.3 42.75 <.001
Placebo group (after vs. before) 9 0.18 0.55, 0.09 48.1 15.42 .051
Intervention group vs. placebo group 9 0.14 0.55, 0.28 77.1 34.8 <.001
HDL-cholesterol Intervention group (after vs. before) 10 0.16 0.41, 0.09 46.7 16.90 .050
Placebo group (after vs. before) 10 0.12 0.42, 0.19 65.0 25.73 .002
Intervention group vs. placebo group 10 0.04 0.36, 0.44 78.7 42.30 <.0001
VLDL-cholesterol Intervention group (after vs. before) 3 0.02 0.51, 0.46 51.2 4.10 .129
Placebo group (after vs. before) 3 0.26 0.20, 0.72 48.3 3.87 .145
Intervention group vs. placebo group 3 0.08 0.24, 0.41 0.0 0.88 .645
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Table 3
The assess of relationship between folate, and blood pressures and lipid proﬁles based on subgroup analysis.
Parameter Number of SMD included Subgroups Pooled OR
(random effect)
95% CI I-squared (%) overall I-squared (%)
Systolic blood pressure Type of diseases 2 Diabetic 0.09 0.52, 0.35 0.0 92.0
4 Non-diabetic 1.32 1.83, 0.09 94.7
Dosage of folate (mg/day) 1 >5 0.36 0.87, 0.15 0.0
5 5 1.00 2.24, 0.25 93.6
Duration of study (week) 4 >8 0.23 0.72, 0.26 55.2
2 8 2.31 6.19,1.56 97.8
Diastolic blood pressure Type of diseases 2 Diabetic 0.36 0.25, 0.97 42.4 92.3
4 Non-diabetic 1.12 2.52, 0.27 94.2
Dosage of folate (mg/day) 1 Diabetic 0.20 0.71, 0.31 0.0
5 Non-diabetic 0.69 1.94, 0.57 93.8
Duration of study (week) 4 >5 0.06 0.34, 0.46 33.9
2 5 2.08 5.80, 1.65 97.8
Triglycerides Type of diseases 4 Diabetic 0.78 0.46, 2.03 92.6 88.0
7 Non-diabetic 0.15 0.73, 0.43 85.9
Dosage of folate (mg/day) 2 >5 0.63 0.51, 1.78 83.7
9 5 0.02 0.60, 0.57 88.3
Duration of study (week) 8 >8 1.51 0.53, 3.56 94.2
3 8 0.22 0.70, 0.25 83.5
Total cholesterol Type of diseases 4 Diabetic 0.11 0.49, 0.71 73.7 74.9
6 Non-diabetic 0.03 0.31, 0.43 79.6
Dosage of folate (mg/day) 2 >5 0.59 0.19, 1.36 66.2
8 5 0.07 0.46, 0.31 72.2
Duration of study (week) 3 >8 0.56 0.07, 1.19 56.4
7 8 0.13 0.52, 0.72 73.5
LDL-cholesterol Type of diseases 4 Diabetic 0.31 0.79, 0.17 59.0 77.1
5 Non-diabetic 0.04 0.64, 0.72 85.4
Dosage of folate (mg/day) 1 >5 0.30 0.62, 0.01 0.0
8 5 1.50 0.69, 2.30 58.3
Duration of study (week) 3 >8 0.19 1.16, 0.78 81.6
6 8 0.13 0.61, 0.36 78.8
HDL-cholesterol Type of diseases 4 Diabetic 0.05 0.42, 0.32 34.3 78.7
6 Non-diabetic 0.05 0.57, 0.66 85.5
Dosage of folate (mg/day) 2 >5 0.68 2.96,1.60 95.5
8 5 0.18 0.16, 0.52 64.0
Duration of study (week) 3 >8 0.12 0.36, 0.59 29.2
7 8 0.01 0.53, 0.52 84.8
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size, after excluding each study from meta-analysis, were
conducted using sensitivity analysis. The results of this analysis
showed that no signiﬁcant difference between pre- and post-
sensitivity analysis on the effect of folate supplementation on lipid
proﬁles (Table 4). The lower and higher summary effect size SMD
sensitivity analyses for lipid proﬁles and related studies into issue
was shown in Table 4.
3.5. Publication bias and risk of bias
In the current study, the publication bias of included studies
was determined using the statistical Egger test. Findings showed
that was not evidence of publication bias between included studies
into meta-analysis for triglycerides (B = 6.80, P = .10), total-
(B = 8.20, P = .08), LDL- (B = 3.44, P = .367), HDL- (B = 5.41,
P = .159), and VLDL-cholesterol (B = 3.45, P = .277) (Fig. 4).
4. Discussion
To our knowledge, this is the ﬁrst meta-analysis of RCTs that
evaluated the effect of folate supplementation on blood pressures
and lipid proﬁles among patients with metabolic diseases. We
found that Folate supplementation did not affect blood pressures
and lipid proﬁles among patients with metabolic diseases.
Therapeutic lifestyle changes aimed at pursuing an acceptable
control of risk factors of metabolic disturbances, comprising
dyslipidemia, insulin resistance and blood pressures, are limited bypoor adherence and persistence [14,15]. Similarly, reduced long-
term compliance to lipid-lowering agents, that is frequently due to
side effects, is a matter of crucial importance in the ﬁeld of
metabolic disorders like diabetes and CVD prevention [16,17].
Therefore, therapeutic strategies which are both effective and safe
in reducing both lipid concentrations are desirable. In a meta-
analysis study conducted by Wang et al. [12], it observed that folate
supplementation was effective in the CVCE among patients with
HT/HHcy, as well as reducing the blood pressure and total
homocysteine levels. In another meta-analysis study conducted
by Qin et al. [18], it was seen that folate supplementation was
effective in reducing the progression of carotid intima-media
thickness (CIMT), particularly in people with chronic kidney
disease (CKD) or high CVD risk and among trials with higher
baseline CIMT levels or a larger total tHcy reduction. Results of
previous epidemiologic studies demonstrated that elevated
circulating levels of tHcy were popular in the general population
and were associated with an increased risk for hypertension, CVD
and stroke [19,20]. Hyperhomocysteinemia may be an important
pathogenic element in the target organ damages, such as
glomerular damage, related to hypertension, as well as CVD
events [21]. Therefore, management of hyperhomocysteinemia
may be helpful to reduce blood pressures and the risk of CVCE.
Insufﬁcient dietary intake of vitamins B, especially folate are
supposed as a main cause of hyperhomocysteinemia. Hence,
attempts to normalize homocystine levels by the supplementation
of these vitamins, such as folate become the main measure [22]. To
our knowledge, few meta-analysis studies have evaluated the
Fig. 3. Meta-analysis of lipid proﬁles standardized mean differences estimates for (A) triglycerides, (B) for total cholesterol, (C) for LDL-cholesterol, (D) for HDL-cholesterol,
and (E) for VLDL-cholesterol in folate and placebo groups (CI = 95%).
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analysis study by Pirro et al. [23], it was seen that taking a
nutraceutical combination comprising red yeast rice, berberine,
policosanol, astaxanthin, CoQ10 and folate (NComb) were signiﬁ-
cant on plasma levels of triglycerides, total-, LDL-and HDL-
cholesterol levels. In addition, NComb-induced amelioration of
lipid fractions was not inﬂuenced by duration of supplementation
nor by baseline lipid concentrations [23]. In addition, the results of
randomised clinical trial about the effects of folate supplementa-
tion on lipid proﬁles are controversial. For example, improved few
lipid proﬁles were observed following the supplementation of
folate in patients with PCOS [24] and patients with MetS [25], but
such beneﬁcial effects were not seen by others [26]. These
differences, along with small patient group sizes might haveprecluded the possibility to reach a deﬁnitive answer on whether
folate administration is really effective in reducing lipid proﬁles. In
the current meta-analysis, the small number of participants per
intervention group not allowed for statistically signiﬁcant changes
to be seen in lipid proﬁles. Whether the overall beneﬁcial effect of
folate supplementation on lipid proﬁles might be greater in large
populations of patients with atherogenic dyslipidemia or with
higher dosage of folate supplements needs to be demonstrated.
Furthermore, it should be pointed out that folate amelioration of
lipid proﬁles may be affected by duration of folate supplementa-
tion and high baseline levels of lipid proﬁles.
Folate supplementation did not affect blood pressures and lipid
proﬁles among patients with metabolic diseases. Additional
prospective studies regarding the effect of folate supplementation
Table 4
The assess of association between folate supplementation and lipid proﬁles based on sensitivity analysis.
Parameter Pre-sensitivity analysis Upper & lower of effect size Post-sensitivity analysis
No. of Studies included Pooled OR
(random effect)
95% CI Pooled OR
(random effect)
95% CI Excluded studies
Systolic blood pressure 6 0.59 1.55, 0.37 Upper 0.01 0.32, 0.30 Setola
Lower 0.85 1.92, 0.21 Mangoni
Diastolic blood pressure 6 0.87 1.83 Upper 0.01 0.32, 0.30 Setola
Lower 0.85 1.92, 0.21 Mangoni
Triglycerides 11 0.10 0.42, 0.63 Upper 0.25 0.21, 0.72 Setola
Lower 0.17 0.57, 0.21 Mangoni
Total cholesterol 10 0.06 0.31, 0.43 Upper 0.15 0.21, 0.51 Sheu
Lower 0.051 0.38, 0.28 Mangoni
LDL-cholesterol 9 0.14 0.55, 0.28 Upper 0.02 0.43, 0.37 Mangoni
Lower 0.30 0.61, 0.11 Kilicdag
HDL-cholesterol 10 0.04 0.36, 0.44 Upper 0.21 0.08, 0.51 Kilicdag
Lower 0.05 0.45, 0.35 Talari
VLDL-cholesterol 3 0.08 0.24, 0.41 Upper 0.61 0.48, 1.71 Asemi
Lower 0.006 0.36, 0.37 Kilicdag
Fig. 4. The summary of review authors' judgments about each risk of bias item for
each included study.
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diseases are necessary.
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